news
Novartis expands in cardiovascular disease with $1.4bn Tourmaline Bio acquisition
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
List view / Grid view
business news
news
Roche en route to first continuous delivery treatment for nAMD in Europe
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
news
Teva wins US obesity approval for its GLP-1 generic liraglutide
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
news
Johnson & Johnson builds on US manufacturing pledge with $2bn Fujifilm investment
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
news
WuXi Biologics granted novel authorisation for commercial biologic manufacturing in Ireland
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
news
Bristol Myers Squibb names new Head of Development
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.
news
Boehringer partnership to advance biologic for rare skin condition
The new partnership between Boehringer Ingelheim and LEO Pharma aims to expand treatment access for more patients with generalised pustular psoriasis.
news
MSD acquisition to accelerate first-in-class COPD drug
The $10 billion acquisition involves advancement of a novel inhaled therapy which has potential to redefine standard of care in respiratory disease.
news
Next drug patent cliff to challenge Big Pharma strategy
While the pharmaceutical market is expected to witness strong pricing competition, there is also significant opportunity for biotech companies, research says.
news
Sandoz breaks ground on new European biosimilar plant
The new investment will help Sandoz to expand its European biosimilar manufacturing capacity and ensure reliable and sustainable supply in the region.
news
AbbVie immunology deal to advance potential first-in-class therapy
The new acquisition, worth up to $2.1 billion, gives AbbVie rights to a potential first-in-class drug for B cell-mediated autoimmune diseases.
news
Gilead partners to advance novel oral oncology drug
The deal between Gilead Sciences and Kymera Therapeutics could lead to development of safer and more effective cancer treatments.
news
Life sciences a “priority sector” in UK Industrial Strategy
The new UK strategy represents a milestone for enhancing international competitiveness and puts into motion the upcoming Life Sciences Sector Plan.
news
Eli Lilly genetic medicine acquisition to address cardiovascular risk
The agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that provide a long-term reduction of cardiovascular risk factors.
news
UCB commits to major US biologics manufacturing investment
The investment will support the company’s long-term vision for its future manufacturing capacity and medicine pipeline.
